secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0000200406-25-000170
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)
----------------------------------------------------------------------------

- Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).
- GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).
- Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).
- Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).
- Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/0000200406-25-000170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm
  HTML page:      https://secwatch.observer/filing/0000200406-25-000170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer